Tuberculosis (TB) is an infectious disease caused by bacteria (Mycobacterium Tuberculosis), which mostly affect the lungs. TB is spread by air and, despite the efforts of prevention and treatment, occurs in every part of the world. About one-third of the world’s population is infected with TB. An accurate and early diagnosis of tuberculosis is a primary strategy of WHO (World Health Organization) in the fight against the disease.
R-Biopharm is developing novel multi-format diagnostic products for the detection of tuberculosis infection. This will allow us to reach out to the new global market and improve life quality of patients in various parts of the globe.
TB is a treatable and curable disease. However, the treatment is usually expensive and requires a long-lasting regimen with multiple antibiotics. Prompt and accurate diagnosis of TB, followed by provisional treatment in line with international standards, limits ill health and prevents deaths.
The TID program at R-Biopharm is focused on developing novel, state-of-the-art diagnostic assays, which provide reliable and highly sensitive solutions to detect tuberculosis infections.
R-Biopharm assays are based on the new IP-10 (interferon gamma-induced protein 10) biomarker, originally discovered and patented by Statens Serum Institute in Denmark. This innovative technology will allow R-Biopharm to offer diagnostic solutions to laboratories and medical hospitals throughout the world. The assays will be provided to the customers in various formats (ELISA, LF, and CLIA) and can be performed manually or on automated platforms.